https://journals.aboutscience.eu/index.php/jcb/issue/feedJournal of Circulating Biomarkers2025-07-28T13:15:48+00:00Lucia Steelelucia.steele@aboutscience.euOpen Journal SystemsJournal of Circulating Biomarkers is an international, peer-reviewed, open access scientific journal focusing on all aspects of the rapidly growing field of circulating blood-based biomarkers and diagnostics using circulating protein and lipid markers, circulating tumor cells (CTC), circulating cell-free DNA (cfDNA) and extracellular vesicles, including exosomes, microvesicles, microparticles, ectosomes and apoptotic bodies.https://journals.aboutscience.eu/index.php/jcb/article/view/3510A comparison of inflammatory markers’ potential to predict weight loss in advanced cancer: a prospective observational study2025-07-28T13:15:48+00:00Ola Magne Vagnildhaugola.m.vagnildhaug@ntnu.noRagnhild H. HabberstadRagnhild.Hansdatter.Habberstad@stolav.noØyvind Salvesenoyvind.salvesen@ntnu.noTrude R. Balstadtrude.r.balstad@ntnu.noAsta Byeabye@oslomet.noOlav Dajaniuxolaj@ous-hf.noStein Kaasastein.kaasa@medisin.uio.noPål Klepstadpal.klepstad@ntnu.noTora S. Solheimtora.s.solheim@ntnu.no<p><strong>Background:</strong> Systemic inflammation is crucial in cancer cachexia, but the optimal measurement method remains<br />unclear. This study compares markers of systemic inflammation (MoSI) in predicting weight loss in patients with<br />metastatic cancer.<br /><strong>Methods:</strong> This prospective, observational multi-center study involved patients undergoing radiotherapy for<br />bone metastases. Baseline assessments included demographics, clinical characteristics, previous weight loss,<br />and appetite loss. MoSI included: C-reactive protein (CRP), albumin, white blood cells, neutrophil-to-lymphocyte<br />ratio, monocyte-to-lymphocyte ratio, interleukin-6 (IL-6), modified Glasgow Prognostic Score (mGPS), and<br />Prognostic Nutritional Index. Body weight was recorded at baseline, 3, and 8 weeks post-radiotherapy. Multiple<br />linear regression assessed MoSI’s predictive ability for weight loss, adjusting for previous weight loss, appetite<br />loss, and primary tumour type. Goodness-of-fit was assessed using adjusted R2.<br /><strong>Results:</strong> Out of 574 recruited patients, 540 and 470 were analyzed at 3 and 8 weeks, respectively. The median age<br />(IQR) was 67 (15), 330 (61%) were male, and 397 (74%) had a Karnofsky performance status ≥70. In a base model<br />without MoSI, significant predictors of weight loss at 3 weeks were appetite loss and urological, lung, and gastrointestinal<br />cancer (adjusted R2 of 0.064), while at 8 weeks, urological and lung cancer were significant (adjusted R2<br />of 0.035). At 3 weeks, all MoSI significantly improved the base model, with adjusted R2 between 0.078 and 0.091.<br />At 8 weeks: CRP, mGPS, albumin and IL-6 improved the model; however only CRP and mGPS retained an adjusted<br />R2 of ~0.09.<br /><strong>Conclusions:</strong> All MoSI predicted weight loss, but CRP and mGPS were the most optimal.</p>2025-07-28T00:00:00+00:00Copyright (c) 2025 Ola Magne Vagnildhaug, Ragnhild H. Habberstad, Øyvind Salvesen, Trude R. Balstad, Asta Bye, Olav Dajani, Stein Kaasa, Pål Klepstad, Tora S. Solheimhttps://journals.aboutscience.eu/index.php/jcb/article/view/3175Soluble interleukin-33 receptor (sST-2): a novel marker for assessing cardiovascular risk in rheumatoid arthritis2025-07-28T13:02:26+00:00Inga ClausInga.Claus@mhb-fontane.deMeike HoffmeisterMeike.Hoffmeister@mhb-fontane.deConstantin Remusconstantin.remus@mhb-fontane.dewerner DammermannWerner.Dammermann@mhb-fontane.deOurania Giotiouraniagioti@hotmail.comOliver Rittero.ritter@uk-brandenburg.deDaniel Patschandaniel.patschan@mhb-fontane.deSusann Patschanspatschan@gmail.com<p><strong>Background:</strong> Rheumatoid arthritis (RA) is the most common inflammatory rheumatic disease, and it significantly<br />increases the risk of cardiovascular disease and death. The evaluation of cardiovascular risk (CVR) is crucial in<br />these patients, but it may be underestimated using the current criteria, as they do not include nontraditional<br />CVR factors. Soluble ST-2, which is the circulating form of the IL-33 receptor, has been identified as a biomarker<br />for cardiovascular and rheumatic diseases. In this study, we examined the role of sST-2 in assessing CVR in RA.<br /><strong>Methods:</strong> Monocentric, retrospective, observational trial. Inclusion of RA patients on variable DMARD therapy.<br />Analysis of RA disease using established scores (DAS 28, VAS, HFQ), clinical findings (number of swollen and painful<br />joints), and laboratory investigation. Documentation of numerous CVR variables. Quantification of soluble<br />sST-2 by ELISA.<br /><strong>Results:</strong> In total, 129 individuals were included. Soluble sST-2 did neither correlate nor was associated with any<br />variable of RA disease activity. In contrast, significant associations were identified between sST-2 and a number<br />of established CVR markers.<br /><strong>Conclusions:</strong> The data indicates a novel role for sST-2 in CVR prediction in RA.</p>2025-07-28T00:00:00+00:00Copyright (c) 2025 Inga Claus, Meike Hoffmeister, Constantin Remus, werner Dammermann, Ourania Gioti, Oliver Ritter, Daniel Patschan, Susann Patschanhttps://journals.aboutscience.eu/index.php/jcb/article/view/3396Irisin and Insulin Interplay in Thyroid Disorders: A Pilot Study2025-06-09T13:34:20+00:00Amisha Malhotraamisha.kmcmlr2023@learner.manipal.eduGayathri Raogayathri.rao@manipal.eduAradhana Marathearadhana.marathe@manipal.eduSowmya Ananda Jothivinod.chandran@manipal.eduVinod Chandranvinod.chandran@manipal.edu<p><strong>Background:</strong> This research was performed to evaluate Irisin and Insulin concentrations in Thyroid patients.<br /><strong>Material and methods:</strong> This investigation was performed as a cross-sectional study within the Biochemistry<br />Department at KMC, Mangalore, and the Central Lab at KMCH-AT, Mangalore. Participants were classified into<br />two cohorts: those having regular thyroid function as well as those having thyroid disorder, including both hypothyroid and hyperthyroid patients, with 28 individuals (n = 28) in each category based on thyroid stimulating<br />hormone (TSH) levels obtained during thyroid dysfunction screenings. Socio-demographic variables like height,<br />weight, and body mass index were calculated, along with the assessment of hypertensive or hypotensive conditions. Insulin levels were quantified using an automated analyzer system. Statistical analyses were performed<br />utilizing Easy-R (EZR) version 1.55, developed by Jichi Medical University in Saitama, Japan. The normal distribution<br />of the parameters was evaluated through normality tests, with t-tests and Kruskal-Wallis tests applied as<br />appropriate.<br /><strong>Results:</strong> Irisin levels significantly declined in hypothyroid individuals while showing an insignificant rise in hyperthyroidism. Insulin levels significantly increased in hyperthyroid patients compared to normal and hypothyroid groups. A positive correlation between insulin and irisin was found in hypothyroidism, while a negative correlation was observed in hyperthyroidism.<br /><strong>Conclusion:</strong> Preliminary findings of this study indicate a potential interdependence between Irisin and thyroid<br />levels. Investigating the interaction between the thyroid profile and irisin can pave the way for considering irisin<br />as a biomarker for novel treatment strategies in thyroid disorders and metabolic conditions.</p>2025-06-09T00:00:00+00:00Copyright (c) 2025 Vinod Chandran, Amisha Malhotra, Gayathri Rao, Aradhana Marathe